Aurinia Pharmaceuticals Inc. Finance Lease, Liability, Current
Aurinia Pharmaceuticals Inc. (AUPH) had Finance Lease, Liability, Current of $16.48 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:FinanceLeaseLiabilityCurrent · last filed 2026-08-06
- 2026-06-30: Finance Lease, Liability, Current $16.48M.
- 2026-03-31: Finance Lease, Liability, Current $16.52M.
- 2025-12-31: Finance Lease, Liability, Current $16.52M.
- 2025-09-30: Finance Lease, Liability, Current $16.31M.
| Period end | Finance Lease, Liability, Current |
|---|---|
| 2026-06-30 | $16.48M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $16.52M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $16.52M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $16.31M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $16.17M 10-Q · filed 2025-07-31 |
| 2025-03-31 | $14.51M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $14.05M 10-K · filed 2026-02-26 |
| 2024-09-30 | $14.93M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $13.91M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $13.72M 10-Q · filed 2024-05-02 |
| 2023-12-31 | $14.61M 10-K · filed 2025-02-27 |
| 2023-09-30 | $13.33M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $14.02M 10-Q · filed 2023-08-03 |
| 2022-12-31 | $0.00 10-K · filed 2024-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B |